Tempus AI (NASDAQ:TEM) Stock Price Up 8.9% – Still a Buy?

Shares of Tempus AI, Inc. (NASDAQ:TEM) were up 8.9% during trading on Wednesday . The company traded as high as $57.93 and last traded at $57.2530. Approximately 3,213,369 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 5,474,323 shares. The stock had previously closed at $52.56.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus unveiled a new AI-powered cancer diagnostic algorithm, a product development that traders view as a revenue/market-momentum catalyst ahead of earnings. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: Robert W. Baird initiated coverage with an “outperform” and a $59 price target, providing institutional validation and upward price support. Baird Initiates Coverage of Tempus AI
• Positive Sentiment: Tempus announced a partnership with Median to add FDA-cleared AI lung‑cancer screening (eyonis LCS) to its Pixel imaging product, expanding its clinical imaging portfolio and addressable market in oncology imaging. Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel
• Neutral Sentiment: Analysts expect strong top-line growth into the quarter (Zacks cites ~82.8% revenue growth expectations), making earnings a key near-term catalyst but not yet proof of sustained profitability. Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
• Neutral Sentiment: Market/valuation pieces are under review — Yahoo Finance and other outlets are assessing valuation after recent share weakness and analyst target dispersion, which keeps investor debate active ahead of results. Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness And Analyst Target Gap
• Neutral Sentiment: Upcoming earnings (expected announcement week) and general market action are additional context drivers; broader market moves could amplify or mute TEM’s reaction to its results. Tempus AI (TEM) Expected to Announce Earnings
• Negative Sentiment: Despite product and partnership wins, some analysts warn that Tempus carries a premium valuation that could limit near-term upside if earnings or guidance fall short of elevated expectations. Valuation Concerns in Zacks Preview

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. JPMorgan Chase & Co. lowered their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. HC Wainwright cut their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Canaccord Genuity Group reduced their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Finally, Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $84.64.

Tempus AI Stock Performance

The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The company has a fifty day moving average price of $63.26 and a 200 day moving average price of $73.60. The stock has a market cap of $9.99 billion, a PE ratio of -47.19 and a beta of 5.22.

Insiders Place Their Bets

In other Tempus AI news, CFO James William Rogers sold 19,966 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the completion of the sale, the chief financial officer owned 111,250 shares in the company, valued at approximately $8,143,500. The trade was a 15.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Erik Phelps sold 1,302 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the completion of the transaction, the executive vice president owned 89,280 shares in the company, valued at $6,019,257.60. This represents a 1.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 710,438 shares of company stock worth $48,629,758. 26.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. increased its position in Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after buying an additional 162 shares in the last quarter. Global Retirement Partners LLC increased its holdings in shares of Tempus AI by 29.5% during the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after acquiring an additional 167 shares in the last quarter. US Bancorp DE raised its position in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after purchasing an additional 176 shares during the last quarter. Legacy Bridge LLC raised its position in shares of Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after purchasing an additional 193 shares during the last quarter. Finally, Truist Financial Corp boosted its stake in Tempus AI by 5.8% in the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after purchasing an additional 194 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.